Anti-MUC1 139H2 reverse engineering

downstream-application

Anti-MUC1 139H2 reverse engineering: downstream-application. Reverse-engineers the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing, MUC1 being a mucin whose aberrant expression and glycosylation matter in…

Reverse-engineers the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing, MUC1 being a mucin whose aberrant expression and glycosylation matter in adenocarcinoma.

Kind	downstream-application
Deep learning	no
Acquisition	DDA
Application area	Antibodyomics

Data

What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.

Papers describing it (3)

Reverse engineering the anti-MUC1 hybridoma antibody 139H2 by mass spectrometry-based de novo sequencing (2023, bioRxiv, preprint)
De novo antibody sequencing based on mass spectrometry (2024, thesis)
Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry–based de novo sequencing (2024, Life Science Alliance, peer-reviewed)

Authors (10)

Weiwei Peng, Koen CAP Giesbers, Marta Šiborová, J Wouter Beugelink, Matti F Pronker, Douwe Schulte, John Hilkens, Bert JC Janssen, Karin Strijbis, Joost Snijder

Seen in the charts

Back to the full map

Data

Evaluated on

Deposited

Also used, purpose not recorded

Papers describing it (3)

Authors (10)

Seen in the charts